Aventis Pharma Limited (t/a Sanofi) is recalling two batches of largactil 50mg/2ml Solution for Injection (chlorpromazine hydrochloride) as a precautionary measure. The affected batches are
| Batch Number: A90142 | Pack Size: 10x2ml ampoules | Expiry Date: 05/2022 | First Distributed: 08 April 2020 |
| Batch Number: A90143 | Pack Size: 10x2ml ampoules | Expiry Date: 05/2022 | First Distributed: 10 June 2020 |
The recall is due to out of specification results obtained for the impurity chlorpromazine sulphoxide, which was suspected to be caused by increased oxidation as a result of higher oxygen content in the headspace of the ampoules.
Healthcare professionals are advised to stop supplying the above batches immediately. Quarantine all stock and return to the supplier.
For stock control enquiries please contact GB-CustomerServices@sanofi.com. Tel: 0800 854 430
For more information or medical information at uk-medicalinformation@sanofi.com. Tel: 0800 035 25 25
Kyowa Kirin Limited is recalling two batches of Abstral 200 microgram sublingual tablets (fentanyl citrate) as a precautionary measure, due to the reports of double tablets in a single blister pocket.
The affected batches are:
| Batch Number | Expiry Date | Pack Size | First Distributed |
| 608973601 | 30 September 2021 | 10 | 9 February 2020 |
| 608973602 | 30 September 2021 | 30 | 28 June 2020 |
Healthcare professionals are asked to quarantine all remaining stock and return it to their supplier.
For Stock control enquiries please contact: Karen Murray, commercial manager, telephone: +44 (0) 7712 001288; e-mail: karen.murray@kyowakirin.com
For medical information enquiries please telephone: + 44 (0)1896 664 000 or e-mail: medinfo@kyowakirin.com
For quality information please contact: Martin Smith (Responsible Person), telephone: +44 7904671807 or
e-mail: Martin.Smith@kyowakirin.com
Kent Pharmaceuticals Ltd is recalling three batches each of Betahistine dihydrochloride 8mg and 16mg tablets due to potential contaminateionwith theophylline. The affected batches are as follows:
Betahistine dihydrochloride 8mg tablets:
| Batch Number | Expiry Date | Pack Size | First Distributed |
| EC10619 | 1 October 2022 | 84 | 21 October 2020 |
| EC10719 | 1 October 2022 | 84 | 9 September 2020 |
| EC10819 | 1 October 2022 | 84 | 4 May 2020 |
Betahistine dihydrochloride 16mg tablets:
| Batch Number | Expiry Date | Pack Size | First Distributed |
| GY11119 | 01 October 2022 | 84 | 21 April 2020 |
| GY11219 | 01 October 2022 | 84 | 05 May 2020 |
| GY11319 | 01 October 2022 | 84 | 23 September 2020 |
Healthcare professionals should quarantine all stock and return it to their suppliers.
If patients experience any side effects related to hypersensitivity or those not normally experienced with betahistine, please refer to a member of the healthcare team and report any suspected side effects via the Yellow Card scheme.
For stock control enquiries please contact customer.service@kent-athlone.com
For more information or medical information medical@kent-athlone.com
